Conventional randomized controlled trials (RCTs) can be expensive, time intensive, and
complex to conduct. Trial recruitment, participation, and data collection can burden …

Purpose of review Racial, ethnic, and gender disparities in cardiovascular care are well-
documented. This review aims to highlight the disparities and impact on a group particularly …

The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases
due to more predictable development pathways and financial incentives. In contrast, drug …

OBJECTIVES: Clinical trials evaluating the safety and effectiveness of sedative medication
use in critically ill adults undergoing mechanical ventilation differ considerably in their …

Cardiovascular diseases (CVD) with escalating death rates pose one of the greatest threats
to global health and well-being. Thus, developing effective interventions to combat CVD are …

There is currently no universally agreed code of practice for patient engagement (PE), and
existing guidelines do not fully cover the scope across medicine development and …

Background Despite calls for the use of additional real-world evidence (RWE) during drug
development, rates of inclusion at the regulatory stage remain low. The medicine adoption …

Cardiovascular disease (CVD) is the primary cause of death and disability worldwide.
Although age-standardized CVD mortality rates decreased globally by 14.5% between 2006 …

The challenge now is the sheer volume of data generated daily, with a single patient
contributing up to 80 megabytes yearly in imaging and electronic health data. 2 Hospitals …

In spring 2018, the American Heart Association convened the Value in Healthcare Summit to
begin an important conversation about the challenges patients with cardiovascular disease …